Phase 2 trial of nivolumab combined with stereotactic body radiotherapy in patients with metastatic or locally advanced inoperable melanoma.

08:00 EDT 2nd April 2019 | BioPortfolio

Summary of "Phase 2 trial of nivolumab combined with stereotactic body radiotherapy in patients with metastatic or locally advanced inoperable melanoma."

Nivolumab improves survival in metastatic melanoma patients. Unfortunately, most patients do not respond to this treatment. Preclinical data indicates that radiotherapy could work synergistically with nivolumab and improve response rates.


Journal Details

This article was published in the following journal.

Name: International journal of radiation oncology, biology, physics
ISSN: 1879-355X


DeepDyve research library

PubMed Articles [15414 Associated PubMed Articles listed on BioPortfolio]

Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial.

To evaluate the dosimetric ramifications of simultaneously irradiating the prostate and pelvic lymph nodes (PLNs) with a stereotactic body radiotherapy approach based on rigid registration to intrapro...

Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase I/II trial for Patients with Low and Intermediate-Risk Prostate Cancer.

This study presents a prospective phase I, IRB-approved dose-escalated stereotactic body radiotherapy (SBRT) trial for prostate cancer (CaP) to assess the impact of dose level on quality of life, toxi...

Reduced motion and improved rectal dosimetry through endorectal immobilisation for prostate stereotactic body radiotherapy.

PROMETHEUS (ACTRN12615000223538) is a multicentre clinical trial investigating the feasibility of 19  Gy in 2 fractions of stereotactic body radiotherapy (SBRT) as a boost technique for prostate can...

Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study.

Some patients are ineligible for intracavitary brachytherapy (ICBT) for locally advanced cervical cancer. Stereotactic body radiotherapy (SBRT) could be a good treatment option for such patients. This...

Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.

Stereotactic body radiation therapy is an emerging treatment for prostate cancer (PC), with potential biological and oncologic advantages. A well-established radiation dosing schedule (38Gy in 4 fract...

Clinical Trials [11341 Associated Clinical Trials listed on BioPortfolio]

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery in treating patients with chordoma that has come back or spread from where it started to ...

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

This phase I/II trial studies the side effects and how well nivolumab and ipilimumab works when given together with stereotactic body radiation therapy (SBRT) in treating patients with sal...

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

The purpose of this study is to see if continued nivolumab with the addition of ipilimumab plus hypo-fractionated stereotactic radiation (sTR) of a single lesions results in partial or com...


This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve re...

Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Nivolumab is an antibody (a type of human protein) that is designed to boost your body's immune system. It does this by allowing immune cells to grow and fight the cancer. Nivolumab has be...

Medical and Biotech [MESH] Definitions

Combined chemotherapy and radiotherapy given to augment some other form of treatment such as surgery. It is commonly used in the therapy of cancer.

Work that is a report of a pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the United States or a foreign country.

Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

The interval between two successive CELL DIVISIONS during which the CHROMOSOMES are not individually distinguishable. It is composed of the G phases (G1 PHASE; G0 PHASE; G2 PHASE) and S PHASE (when DNA replication occurs).

Trial that aims to show a new treatment is no better and no worse than the standard treatment.

Quick Search


DeepDyve research library

Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

Searches Linking to this Article